Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours
2023-504246-64-00Phase 2Withdrawn
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Oct 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrilatazar in neuroblastoma and Nonhematologic neoplasms, sponsored by Vall d'Hebron Research Institute. Primary endpoint: Incidence of dose limiting toxicities. Planned start Oct 2023; status: withdrawn.
02
Drugs
ibrilatazar
03
Conditions
neuroblastomaNonhematologic neoplasms
Beyond the preview
Go deeper on 2023-504246-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504246-64-00.